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Abstract: Introduction: During the manufacturing of sterile drugs, it is of the utmost importance to meet the minimum requirements for asepsis
recommended by the legislations on good manufacturing practices-based efficient environmental monitoring. Aims and methods: The availability of
relatively simple to use matrix-assisted laser desorption ionization–time of flight mass spectromtomy (MALDI-TOFMS) devices in the last years has
changed the laboratory workflows for the microbial identification, mainly in the clinical area. Thus, the objective of this work was to evaluate the
suitability of the MALDI-TOF MS technique for the identification of bacteria isolated from the environment of clean rooms used in some stages of
the production of a viral vaccine. Eighteen known bacterial species commonly isolated from clean rooms studied were identified by MALDI-TOF
technique and by a biochemical technique (BBL Crystal® System). Results: Performance of MALDI-TOF MS was better than biochemical technique
for correct species identifications (88.89% and 38.89%, respectively) and produced less unreliable identification (5.55% and 22.22%). Conclusion:
MALDI-TOFMS can be implemented for routine identification of bacteria in a pharmaceutical quality control laboratory, but as a database-dependent
system, maybe some isolated not identified by this technique must be additionally studied and, if appropriate, added to an in-house database.
Keywords:MALDI-TOFMS identification, bacterial identification, biochemical identification, rapid microbiological methods, pharmaceutical clean
room, environmental monitoring
Introduction
Biological products are the largest source of innovation
in the pharmaceutical industry and have played an im-
portant role in the treatment of various diseases that had
not been effectively treated with traditional therapies to
date [1, 2]. Specifically, vaccines are the group of bio-
logical products, which represent the historically most
effective ways of preventing diseases [3]. During the
vaccine-production process, comprehensive and rigid
guidelines must be followed to obtain a safe product.
Among the requirements, clean rooms are prerequisite
to obtain a safe product [4]. According to the United
States Pharmacopeia 38 (USP 38) compendium, in
addition to attending different analytical aspects of the
product, it is necessary to evaluate a set of particularities
of the process for the release of sterile products.
When considering the non-applicability of terminal
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sterilization, special emphasis is given to environmental
monitoring [5].
Clean rooms are controlled environments that require
an efficient Environmental Monitoring Program. Thus,
this program must be capable of detecting an adverse
event in microbiological conditions in time to allow
effective corrective actions. The principle aim is control-
ling the levels of microorganisms and particles within
specific limits, in addition to monitoring microbial diver-
sity [6]. Knowledge of the normal microbiota of clean
rooms is important to provide useful information in the
investigation of sources of contamination, especially when
the limits of action are exceeded [4, 6]. Identifying this
microbiota is also necessary to establish which microor-
ganism should be used in the validation and evaluation of
the growth promoter capacity of culture media for envi-
ronmental monitoring [7].
Many technologies aimed at microbial identification
with different evolutionary levels and applying varied
resources have been developed. In the early stages of this
evolutionary process, the research was directed and ap-
plied to the clinical area, to identify and correct the
antibiotic therapy. Following this, great efforts were made
in the area of food: the nature and origin of the inputs
used in this segment provide the possibility of a wide
range of contaminants. Finally, all current targeting is
aimed at drugs, complex group as to route of adminis-
tration, distinct risk groups, and among others. However,
the implementation of new technologies in the pharma-
ceutical field has been delayed due to the highly regulated
environment in which the pharmaceutical industry works
with a conservative approach and the need for strict
validation requirements [4]. Currently, the classical mi-
crobial identification methods available to the microbio-
logical pharmaceutical control laboratories and accepted
by regulatory authorities are based on culture methods
[4, 8]. By adopting the biochemical and physiological
comparison of certain characteristics, such as the mor-
phology of the colonies and the potential to ferment
certain sugars, a profile of the microorganisms present
in the clean rooms can be obtained. However, these
conventional methods are often time-consuming and can
take up to 6 weeks to obtain the result [9–11]. Thus, it is
necessary to constantly search for new technologies to
accelerate this response time.
The development of rapid microbiology methods by
pharmaceutical companies can be considered as an irre-
versible tendency in the pharmaceutical field, since they
are currently looking for new and more efficient tools to
speed up and improve the quality level of the analytical
results, including those of microbial identification. In
addition to reducing the time of analysis, these methods
are more assertive and efficient, require a small amount of
material, and reduce the added value of the analysis
[4, 12]. Different technologies have originated products
for the rapid identification of microorganisms using
biochemical methods, such as the API®, VITEK®, and
Biolog® galleries; systems based on the use of substrates
to obtain the identification of the isolates, such as
Crystal® miniaturized identification system and Micro-
ID®; gas chromatography of fatty acids; and molecular
biology-based systems such as Gene-Trak®, BAX®,
MicroSeq®, and Riboprinter® [4].
From the techniques available for rapid and automated
methods, mass spectrometry based on the matrix-assisted
laser desorption ionization technology (MALDI-TOF) is
the one that arouses the highest interest [13]. It is an
accurate and cost-effective method of bacterial identifica-
tion developed in mid-1980s [14, 15]. Among the phys-
icochemical techniques that allow the detection and
characterization of microorganisms, it presents a unique
combination of rapidity, high specificity, and excellent
sensitivity essential for microbial analysis. These attributes
combined with their ready adaptability to the direct
analysis of fungi and bacteria and the demand for low-
cost reagents makes this technique an attractive option for
laboratories in clinical, pharmaceutical, environmental,
and food microbiology [16].
Parenteral Drug Association technical report no. 33 is
intended to fill the gap that prevents the widespread
adoption of alternative rapid microbiological methods.
The aim was to achieve this objective by establishing
how to demonstrate the equivalence of these methods to
existing ones in a manner acceptable to regulatory agen-
cies and how to validate equipment associated with the
alternative rapid method [12]. Both USP and European
Pharmacopeia have specified the steps necessary for
the validation of an alternative microbiological method
(USP General Information Chapter 1,223 Validation of
Alternative Microbiological Methods and Ph. Eur. In-
formational Chapter 5.1.6 Alternative Methods for Con-
trol of Microbiological Quality, respectively) [17, 18].
Validation of Compendial Procedures chapter 1,225
(USP 38) defines some essential characteristics in their
application to analytical methods, as detection limit,
quantification limit, linearity, and range [17]. The nec-
essary procedure for verification of an alternative micro-
bial identification method can be done in three ways as
follows: (1) using an existing system for parallel testing of
microbial isolates obtained from routine testing (the
number of isolates tested may be as high as 50, and any
discrepancies in identification can be arbitrated using a
referee method); (2) testing 12–15 known representative
stock cultures of different commonly isolated species for
a total of 50 tests; or (3) confirming that 20–50 organism
identifications, including 15–20 different species, agree
with the results of a reference laboratory testing of split
sample.
In this study, we selected the most appropriate study
conditions (number 2) and followed the steps established
to USP 38, the main guide for verification of microbial
identification methods. Thus, the objective of this work
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was to evaluate the suitability of the MALDI-TOF MS
technique for the identification of bacteria isolated from
the environment of clean rooms used in some stages of
the production of a viral vaccine in comparison with a
biochemical identification method.
Materials and Methods
Bacterial isolates and sampling
Thirteen bacterial isolates were recovered from routine
identification of samples deriving from the Environmental
Monitoring Program of Clean Rooms and selected for
the study. Such samples were taken from the air and
surfaces of clean rooms used in some stages of the
production of a viral vaccine as well as operators of these
rooms. Five reference microorganisms from the American
Type Culture Collection (ATCC) were also included in
the study (Table I).
The sampling of airborne microorganisms was made
with impaction sampler M Air T® (Merck Millipore,
Billerica, MA, USA) and sterile Petri dishes, adaptable to
the apparatus, containing commercially purchased tryptic
casein soy agar. About 1 m3 of air was tested during an
exposure time of 15 min. Settling plates containing tryptic
casein soy agar commercially purchased were also exposed
for sampling airborne microorganisms during 4-h period.
The sampling of regular or flat surfaces and personnel were
accomplished using contact plates containing tryptic casein
soy agar commercially purchased.
Culture conditions and stock culture
The isolates were recovered after aerobic incubation
at 32.5 ± 2.5 °C for 48 h, and in the sequence at
22.5± 2.5 °C for 72 h, totaling 120 h of incubation.
Then, the colony forming units were identified by
MALDI-TOF MS in duplicate and the stock cultures
were maintained on tryptic casein soy agar at 32.5±
2.5 °C and subcultured each month until fifth passage.
From this stock culture, previously identified by MALDI-
TOFMS for reference results were made identifications in
triplicate for comparison between biochemical and
MALDI-TOF MS methods.
Biochemical identification
After Gram staining and determination of catalase and
oxidase activities, bacterial isolates and reference strains
were identified by appropriate BBL Crystal® identifica-
tion systems for Gram-positive and Gram-negative bac-
teria, both according to the manufacturer’s instructions.
Mass spectrometry
A thin smear of bacteria was deposited on a MALDI plate
in triplicate. Each smear was overlaid with 1 μL of matrix
solution (α-ciano-4-hydroxycinnamic acid). The matrix
sample was co-crystallized by air drying at room temper-
ature. Measurements were performed with a Biomerieux
mass spectrometer (Vitek® MS) using the software
LaunchPad – Shimadzu Biotech MALDI-MS (version
2.8, Shimadzu Scientific Instruments, Kyoto, Japan).
Saramis Target Manager program and Saramis Premium
system were used for interpretation of spectra obtained.
For each spectrum, 100 shots from different positions of
the target spot (automatic mode) were collected
and analyzed. Spectra were internally calibrated using
Escherichia coli ATCC 8739 cultivated in MacConkey
agar. Results were expressed as proposed by the
manufacturer with scores ranging from 0% to 99.9%.
Scores below 90% were considered not to have generated
a reliable identification; scores above 90% were consid-
ered reliable both for genus and species identification.
Criteria for identification
The previously MALDI-TOF identifications were con-
sidered final (reference identifications). The results of the
tested methods were considered correct only when they
had exactly the same identification to the species level of
the reference identifications. Scores below 90% were
considered not to have generated a reliable identification.
Discrepant results on a triplicate test within the same
Table I Microorganisms selected for the study






Microorganisms isolated from clean rooms studied
Gram-positive Gram-negative
Micrococcus luteus Stenotrophomonas maltophilia
Staphylococcus epidermidis Acinetobacter johnsonii
Staphylococcus cohnii Chryseobacterium indologenes
Staphylococcus capitis Pseudomonas aeruginosa
Staphylococcus saprophyticus Delftia acidorovans
Staphylococcus warneri Ralstonia panila
Bacillus cereus group –
Obs.: The stock cultures of the bacterial species selected for the study
were identified by MALDI-TOF mass spectrometry method
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range (above 90%) (e.g., Staphylococcus simulans vs.
Staphylococcus saprophyticus) were considered not uni-
form. For comparisons between biochemical and
MALDI-TOFMS identification methods, a Fisher’s exact
test was performed using GraphPad Prism version 5.00,
(GraphPad Software, La Jolla, CA, USA), because it is the
most appropriate test for the calculation of p value when
the samples are small.
Results
The results of bacteria identifications by both MALDI-
TOF MS and biochemical method are presented in
Tables II and III, respectively. Of the 18 bacterial
species selected for evaluation of the MALDI-TOF MS
method, 16 (88.9%) were correctly identified by this
technique at the genus and species levels: Staphylococcus
cohnii, S. saprophyticus, Micrococcus luteus, Staphylococcus
epidermidis, Staphylococcus capitis, Staphylococcus warneri,
Bacillus cereus group, Stenotrophomonas maltophilia,
Acinetobacter johnsonii, Pseudomonas aeruginosa, Delftia
acidorovans, Staphylococcus aureus ATCC 6538, Bacillus
spizizenii ATCC 6633, Salmonella typhimurium ATCC
14028, P. aeruginosa ATCC 9027, and E. coli ATCC
8739. Only one species (Ralstonia panila) was not cor-
rectly identified (5.5%) and another (Chryseobacterium
indologenes) (5.5%) resulted in a score below that consid-
ered reliable by the manufacturer (90.0%).
The identifications by BBL Crystal® system yielded 12
(66.6%) correct identifications at the genus level:
S. cohnii, S. saprophyticus, M. luteus, S. epidermidis,
S. capitis, S. warneri, B. cereus group, S. maltophilia,
B. spizizenii ATCC 6633, S. typhimurium ATCC 14028,
Table II Identification results of bacterial species selected for the study by MALDI-TOF MS














Staphylococcus cohnii 2 2 – – – 1
Staphylococcus
saprophyticus
3 3 – – – –
Micrococcus luteus 3 3 – – – –
Staphylococcus epidermidis 3 3 – – – –
Staphylococcus capitis 3 3 – – – –
Staphylococcus warneri 3 3 – – – –
Bacillus cereus group 3 3 – – – –
Stenotrophomonas
maltophilia
1 1 – – – 2
Acinetobacter johnsonii 2 2 – – – 1
Chryseobacterium
indologenes
– – – – – 3
Pseudomonas aeruginosa 3 3 – – – –
Delftia acidorovans 1 1 – – – 2
Ralstonia panila – – 3 – – –
Staphylococcus aureus
ATCC 6538
3 3 – – – –
Bacillus spizizenii ATCC
6633
3 3 – – – –
Salmonella typhimurium
ATCC 14028
2 2 – – – 1
Pseudomonas aeruginosa
ATCC 9027
2 2 – – – 1
Escherichia coli ATCC
8739
3 3 – – – –
aBacterial species were tested in triplicate by MALDI-TOF MS and by biochemical identification methods according to manufacturer’s descriptions,
for a total of 54 tests.
bScores below 90% were considered not to have generated a reliable identification
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P. aeruginosa ATCC 9027, and E. coli ATCC 8739.
Of these, seven (38.8%) bacterial species were correctly
identified at the species level: S. cohnii, S. epidermidis,
S. capitis, S. maltophilia, B. spizizenii, P. aeruginosa
ATCC 9027, and E. coli.
Two (11.1%) species were misidentified by BBL Crys-
tal® system (C. indologenes and D. acidorovans), four
(22.2%) did not obtain a sufficient score value to be
accepted (90.0%) (A. johnsonii, P. aeruginosa, R. panila,
and S. aureus ATCC 6538) and two (11.1%) resulted in
non-uniform identifications (S. saprophyticus and M.
luteus), where acceptable scores were obtained, but with
discrepant identifications to the species level or no iden-
tification to the species level in some of the three
replicates.
Performance of MALDI-TOF MS was better than
biochemical technique in all aspects analyzed: correct
species identifications (88.89% and 38.89%, respectively),
correct identification only at the genus level (0% and
16.67%, respectively), unreliable identifications (scores
below 90%) (5.55% and 22.22%), non-uniform identifi-
cations between triplicates (0% and 11.11%), and
misidentifications (5.55% and 11.11%, respectively)
(Table IV).
P values were calculated by comparison of MALDI-
TOF MS identification with biochemical identification
(Fisher’s exact test) (Table V). The measures of accuracy
at genus and species level are shown in Table VI.
Discussion
Microorganisms are virtually found in all environments.
Since the optimal conditions of survival and growth of
Table III Identification results of bacterial species selected for the study by BBL Crystal®














Staphylococcus cohnii 1 1 – – – 2
Staphylococcus
saprophyticus
3 2 – 1 – –
Micrococcus luteus 3 1 – – – –
Staphylococcus epidermidis 3 3 – – – –
Staphylococcus capitis 3 3 – – – –
Staphylococcus warneri 3 – 3 – – –
Bacillus cereus group 3 – 3 – – –
Stenotrophomonas
maltophilia
3 3 – – – –
Acinetobacter johnsonii – – – – 2 1
Chryseobacterium
indologenes
– – 3 – – –
Pseudomonas aeruginosa – – – – – 3
Delftia acidorovans – – 2 – 1 –
Ralstonia panila – – – – – 3
Staphylococcus aureus
ATCC 6538
– – – – – 3
Bacillus spizizenii ATCC
6633
3 3 – – – –
Salmonella typhimurium
ATCC 14028
3 – – – – –
Pseudomonas aeruginosa
ATCC 9027
1 – – – – 2
Escherichia coli ATCC
8739
3 3 – – – –
aBacterial species were tested in triplicate by MALDI-TOF MS and by biochemical identification methods according to manufacturer’s descriptions,
for a total of 54 tests.
bScores below 90% were considered not to have generated a reliable identification
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many of them coincide with which the human popula-
tions live, it is inevitable to coexist with large numbers of
them. They are on the surface of the human body, as well
as in the digestive tract and other natural orifices. This
ubiquity and the risk that the microbial contamination of
drugs offers to the users evidence the importance of the
microbiological control of the productive areas [19].
In an Environmental Monitoring Program, the sam-
pling frequency depends on the criticality of the moni-
toring sites and the treatment to which the product is
subjected after the aseptic process. Environmental moni-
toring needs considerable attention when the product
is potential to personal contact during manufacturing
or not submitted to the terminal sterilization. The greater
the potential for personal contact with the product,
the greater the importance of environmental monitoring,
as well as for products not submitted to terminal
sterilization [17]. Independently of the degree of sophis-
tication, any Environmental Monitoring Program will
not be able to identify and quantify all microbial con-
taminants present in controlled environments. However,
a well-planned and executed routine monitoring provides
sufficient information to determine that the controlled
environment is operating within a suitable control
state [19].
The presence of certain microbial species in clean
pharmaceutical rooms may be related to risk factors. It
is emphasized that in injectable products, the criticality is
independent of the nature of the microorganism. Never-
theless, it should be considered that Gram negative,
besides offering microbiological risk, can induce pyro-
genic reactions in the patient. On the other hand, those
that are characterized by high pathogenicity may be
producing different toxins [4].















Species ID (%) 7 (38.89%) 0 0 0 0 7 (38.89%)
Genus ID (%) 3 (16.67%) 0 0 0 0 3 (16.67%)
No ID (%) 3 (16.67%) 0 0 0 1 (5.55%) 4 (22.22%)
No uniform ID (%) 2 (11.11%) 0 0 0 0 2 (11.11%)
Misidentification (%) 1 (5.55%) 0 1 (5.55%) 0 0 2 (11.11%)
Total (%) 16 (88.89%) 0 1 (5.55%) 0 1 (5.55%) 18 (100%)
The selected bacterial species were tested in triplicate by MALDI-TOF MS and BBL Crystal® system, according to the manufacturer’s instructions.
For both methods, the acceptable minimum score was 90% for both genus and species identifications. ID species: identification at the species level;
Genus ID= correct identification only at genus level; No ID: scores below 90%; No uniform ID: discrepant results on triplicate test within the same
range (above 90%); Misidenification: misidentification at the genus or species level
Table V Identifications by MALDI-TOF MS and BBL Crystal® system compared to the final identifications
Identification parameter
MALDI-TOF MS identification
[no. of isolates (%)]
BBL Crystal® identification
[no. of isolates (%)] P valuea
Genus correct 16 (88.89%) 12 (66.67%) NS
Species correct 16 (88.89%) 7 (38.89%) <0.01
No identification 1 (5.55%) 4 (22.22%) NS
No uniform identification 0 2 (11.11%) NS
Misidentification 1 (5.55%) 2 (11.11%) NS
The selected bacterial species were tested in triplicate by MALDI-TOF MS and BBL Crystal® system. Final identifications were established by prior
analysis performed by MALDI-TOF MS with scores above 90%, as recommended by the manufacturer.
aNS: not statistically significant
Table VI Measure of accuracy at genus and species level for MALDI-TOF MS and BBL Crystal system
MALDI-TOF MS BBL Crystal
Criteria for identification Number of correct results Accuracy (%) Number of correct results Accuracy (%)
Species level 16 88.89 7 38.89
Genus level 16 88.89 12 66.67
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In this study, the choice of microorganisms was based
on high isolation frequency of these species in clean
rooms as evident from the literature [20–22]. Utescher
et al. [20], in an evaluation study of the Environmental
Monitoring Program for clean pharmaceutical rooms in a
Brazilian production of biological medicines, observed
that the typical microbial population was composed of
bacteria of the genera Staphylococcus sp., Micrococcus sp.,
and Bacillus sp., with predominance of Staphylococcus spin
all the areas. These three bacterial genera have a ubiqui-
tous distribution. They have been isolated from the
environment or on human skin and mucous membranes.
Therefore, the study of presence of the species of these
genera needs more attention in microbial identification
methods in pharmaceutical production. Therefore, the
importance of the presence of species of these genera in
studies on the adequacy of microbial identification meth-
ods is used in the context of pharmaceutical production.
Sandle [21], in his review on the typical microflora of
clean pharmaceutical rooms, examined several clean areas
located in various establishments in England and Wales
used for the manufacture of blood products from 2001
to 2009. Recovered microorganisms were represented
by six main genera, among them, Staphylococcus sp.,
Micrococcus sp., Bacillus sp., and Pseudomonas sp. The
most frequent species in these environments were M.
luteus, S. epidermidis and S. capitis. Abreu et al. [22]
also found a high frequency of the genus Bacillus sp. and
Staphylococcus sp. in their study on environmental moni-
toring of clean areas.
Fungi and yeast have not been primarily addressed in
this study because they were not frequently isolated in
clean rooms studied also because, as described in the
literature, the analysis of these microorganisms by
MALDI-TOF MS is still fragile due to the low reproduc-
ibility. In addition, the effects of their different physio-
logical states on the reliability of identification methods
are still controversial [23]. MALDI-TOFMS-based iden-
tification of yeast also requires a pretreatment of the yeast
sample before the acquisition of the spectra, involving a
complete extraction of the fungal material [24]. This
process needs to be studied more deeply for the identifi-
cation of fungi isolated from the environment of phar-
maceutical clean rooms.
Rapid and accurate identification of microorganisms is
an essential part of pharmaceutical analysis and besides
having these characteristics, MALDI-TOF technology
has been widely used in microbiological laboratories,
especially those in the clinical area [25]. However, in the
case of laboratories for microbiological quality control of
pharmaceutical products, studies are limited, making it
difficult to compare the results obtained from this tech-
nique with those obtained in the same context of envi-
ronmental isolates.
The spectra libraries that make up the databases of the
mass spectrometers available for microbial identification
have their focus on clinical microbiology. This makes it
difficult to apply the technique in the clean room area,
since it is not possible to know in advance the character-
istics of the microorganisms, which will be isolated. This
difficulty demands improvement of the libraries and
techniques of sample preparation, since the compositional
variability of the microorganisms that can be found in the
environment is very large and interferes with the accuracy
of the technique [25–27].
However, the results of this study revealed an excellent
performance of MALDI-TOF MS in comparison with
conventional identification technique (biochemical identi-
fication) for correct species identification (88.89%
and 38.89%, respectively). Other authors also found the
same evidence, although it has not been isolated micro-
organisms from the environmental monitoring of pharma-
ceutical clean rooms. Veen et al. [28] performed a study
with 1,307 clinical isolates of bacteria and yeasts of several
genus, such as Klebsiella sp., Pseudomonas sp., Salmonella
sp., Staphylococcus sp., Streptococcus sp., and Candida sp.
Overall performance ofMALDI-TOFMSwas significantly
better than conventional biochemical systems (Vitek-II,
API, and biochemical tests) for correct species identifica-
tion (92.2% and 83.1%, respectively) [28].
Guo et al. [29], in a comparative study of MALDI-
TOF MS and Vitek 2 in bacteria identification, found an
accuracy of 96.5% and a lower identification error rate in
MALDI-TOF MS performance, making it better at iden-
tifying bacteria than Vitek 2. The bacteria were routinely
isolated from clinical patients of a General Hospital in
Beijing]. Seng et al. [30] also reported that MALDI-TOF
MS can replace conventional systems for identification of
bacteria in a conventional clinical laboratory. Of 1,660
bacterial isolates analyzed, 95.4% were correctly identified
byMALDI-TOFMS; 84.1% were identified at the species
level, and 11.3% were identified at the genus level.
In most of the study, Vitek 2 system is used as a
biochemical method for comparison with the MALDI-
TOF technique. No studies were found using the BBL
Crystal system as a conventional method to compare the
results.
The microbiological method of BBL Crystal®
biochemical identification was chosen for comparison
with the MALDI-TOF MS technique, although it is
also considered a rapid method. This is due to the fact
that this miniaturized system was developed accord-
ing to the principle of microbiological methods for
microbial identification, that is, culture in appropriate
culture media to demonstrate the physiological char-
acteristics of each microorganism capable of differenti-
ating them from the others. Thus, some limitations
of these methods can still be found in BBL Crystal®,
such as the variability of the microorganisms in their
response to the culture media, causing subjectivity in
the reading of the results, which, in turn, can lead to
misidentifications [31].
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The greater importance of this study is the implemen-
tation of MALDI-TOF MS in a routine setting of
pharmaceutical clean rooms and the comparison of
MALDI-TOF MS with conventional identification
systems on environmental isolates. A limitation of this
study is the lack of use of 16S DNA sequencing for analysis
of discrepancies, once the traditional identification of
bacteria on the basis of phenotypic characteristics is gen-
erally not as accurate as identification based on genotypic
methods [32]. However, good results obtained with
MALDI-TOF technology and described in the literature
over the years can minimize this limitation [33].
In addition to being a much less labor-intensive tech-
nique capable of delivering accurate and reliable results in
a few minutes from a single isolated colony, MALDI-
TOF MS can also generate significant cost savings for
laboratories. Tran et al. [34] reported the advantages of
MALDI-TOF MS technique compared with convention-
al methods. The authors carried out a comparative study
to determine the amount that can be saved by the
laboratories when replacing the biochemical identifica-
tion methods with the MALDI-TOF MS technique.
A total cost analysis was done, including reagent costs,
technologist time, and maintenance service expenses. The
use of the MALDI-TOF MS technique resulted in an
annual saving of 51.7% and the initial acquisition cost
of the equipment, although high can be recovered in
approximately 3 years.
Conclusions
In conclusion, MALDI-TOF MS is a simple, rapid, and
inexpensive technique for identification of bacteria, in-
cluding bacteria isolated from pharmaceutical clean room
environmental monitoring, and can be implemented in a
conventional pharmaceutical quality control laboratory
setting. Although the technique has a high accuracy for
bacterial identification, the performance can be improved
with the improvement of the databases.
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